Skip to main content
. Author manuscript; available in PMC: 2022 Oct 7.
Published in final edited form as: J Thromb Haemost. 2021 Nov 21;20(1):32–38. doi: 10.1111/jth.15579

TABLE 2.

Drugs targeting FXI(a) undergoing testing in clinical trials

Drug Drug type Mechanism of action Administration route Effective half-life
IONIS-FXIRx DNA antisense oligonucleotide Reduces level of FXI antigen in plasma Subcutaneous Days to weeks
Osocimab Monoclonal antibody FXIa active site inhibitor Intravenous or subcutaneous Days
AB023 Monoclonal antibody Binds FXI and interferes with conversion to FXIa Intravenous or subcutaneous Days
Abelacimab Monoclonal antibody Binds FXI, interferes with conversion to FXIa and inhibits FXIa activity Intravenous or subcutaneous Days
Milvexian Small molecule FXIa active site inhibitor Oral Hours
BAY-243334 Small molecule FXIa active site inhibitor Oral Hours

Abbreviations: FXI, factor XI; FXIa, activated form of factor XI.